ArticleScientific reports2026
Biological activity of Pleurotus eryngii based on antioxidant, anticholinesterase and antiproliferative effects using optimized extraction methods.
Article in Scientific reports, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
This study aims to evaluate the antioxidant potential, anticholinesterase activity, antiproliferative effects, and phenolic contents of optimized extracts derived from Pleurotus eryngii. Single-objective and multi-objective optimized extracts of P. eryngii were analyzed using antioxidant assays (TAS, TOS, DPPH, FRAP, and OSI), anticholinesterase activity (AChE and BChE inhibition), and antiproliferative activity against the A549 lung cancer cell line. Additionally, phenolic compositions were determined via LC-MS/MS analysis under optimized extraction conditions. The single-objective extract exhibited higher TAS values (7.212 ± 0.060 mmol/L) compared to the multi-extract (5.682 ± 0.054 mmol/L), while the multi-objective extract demonstrated higher TOS and OSI values. Both extracts showed significant anticholinesterase activities, with IC₅₀ values indicating stronger inhibition compared to previously reported studies. The single-objective extract displayed superior antiproliferative activity against A549 cells, and both extracts showed dose-dependent effects. LC-MS/MS analysis revealed that phenolic compounds such as gallic acid, caffeic acid, and protocatechuic acid were more abundant in the single-objective extract. The optimized extracts of P. eryngii demonstrated substantial antioxidant, anticholinesterase, and antiproliferative activities, with the single-objective extract showing enhanced bioactivity compared to the multi-objective extract. While P. eryngii presents a promising natural source of antioxidants and enzyme inhibitors, its relatively high oxidant production potential suggests that further toxicological evaluation is required to assess its safe use. Further studies are recommended to enhance extraction methods and explore molecular mechanisms underlying its therapeutic properties.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.